Regulated information january 29, 2013

TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid

Leuven (BELGIUM), Madrid (SPAIN) - January 29, 2013 - TiGenix (Euronext Brussels: TIG), a leader in the field of cell therapy, announced today that further to the cGMP inspection by the Spanish health authorities it has successfully renewed its manufacturing authorization for stem cell products at its manufacturing facility in Madrid, Spain.

"The GMP facility in Madrid performs a vital function within our organization by manufacturing high-quality, clinical grade allogeneic stem cell products to fuel our key clinical programs," said Wilfried Dalemans, CTO of TiGenix. "It is an important stepping stone before we can move to commercial manufacturing at our state-of-the-art, central GMP manufacturing site in Sittard-Geleen, the Netherlands. Our strong cell therapy manufacturing capabilities place us at the forefront of the cell therapy industry."

For more information: Eduardo Bravo Claudia D`Augusta Chief Executive Officer Chief Financial Officer eduardo.bravo@tigenix.com claudia.daugusta@tigenix.com Hans Herklots hans.herklots@tigenix.com +32 16 39 79 73

About TiGenix

TiGenix NV (Euronext Brussels: TIG)is a leading European cell therapy companywith a marketed product for cartilage repair, ChondroCelect, and a strongpipeline with clinical stage allogeneic adult stem cell programsfor the treatment ofautoimmune and inflammatory diseases.TiGenixis based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (theNetherlands). For more information please visitwww.tigenix.com.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix` control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix` expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

Originally posted here:
TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid